Evaluation of WO2013116562A, an orally active PI3Kδ inhibitor for the treatment of asthma

Abstract

(S)-4-amino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile is claimed as a highly selective, PI3Kδ inhibitor. It is claimed to be useful in the treatment of asthma and appears intended for oral administration. It is shown to be well absorbed after oral administration and to have reasonable metabolic stability

Keywords::

• asthma
• duvesilib
• GSK-2269557
• idelalisib
• PI3Kdelta inhibitor
• rheumatoid arthritis